Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSome people starting semaglutide (Wegovy) notice changes to their vision and want to know whether this is expected, rare, or a reason to stop treatment. The short answer: most vision-related reports are uncommon and context-dependent, but a small number of situations do require prompt medical attention. Here is what the clinical evidence shows, and how to decide what to do if you notice something. Like all prescription-only medicines, Wegovy requires clinical assessment before starting — and our prescribers cover potential side effects, including the full Wegovy side-effect profile, as part of every consultation.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Wegovy's patient information leaflet lists vision disturbance among possible side effects, but the picture is more nuanced than a simple yes or no. The highest-profile concern is diabetic retinopathy complications, a worsening of existing eye disease that has been recorded in people with type 2 diabetes using semaglutide. In the SUSTAIN 6 cardiovascular outcomes trial (which used the diabetes formulation, not Wegovy), retinopathy complications occurred more often in the semaglutide group than in placebo. The leading explanation is that very rapid reduction in blood glucose, rather than the drug itself directly damaging the eye, is the trigger. Fast metabolic change can temporarily affect the tiny blood vessels already stressed by years of poorly controlled diabetes.
For people without type 2 diabetes (which describes most people taking Wegovy for weight management) this specific mechanism does not apply in the same way. General vision changes such as mild blurring were reported during the STEP clinical programme, but at low rates and typically transiently. If you are uncertain about your own risk, the NHS semaglutide medicines page sets out the listed side effects in plain language, and our clinical team discusses individual circumstances during assessment. People starting Wegovy after reading about mood-related semaglutide side effects often ask about vision at the same time, both are worth raising at consultation.
The decision this page is really about is whether a change you have noticed is one to monitor or one to act on immediately. The answer depends partly on what you are experiencing and partly on your medical history.
Get same-day medical attention if you notice: sudden blurred vision or vision loss in one or both eyes; a shadow or curtain across part of your visual field; a significant change in colour perception; a dramatic increase in floaters or flashes of light; or any eye change accompanied by headache, pain, or nausea that is distinct from the typical gastrointestinal side effects of semaglutide. These patterns can be signs of conditions unrelated to Wegovy but that happen to occur during treatment. Time matters for most acute eye conditions regardless of their cause.
People with a pre-existing diagnosis of diabetic retinopathy should have their retinopathy status reviewed before starting semaglutide, the NHS and the SmPC both flag this. Our prescribers ask about eye health as part of the standard medical history; it is one of the reasons clinical assessment exists. You can read more about the broader set of side effects associated with Wegovy to get context for where vision sits in the overall picture.
One check that takes under a minute and is worth doing within the first few weeks of starting: cover each eye in turn and look at a straight line, a door frame, a window edge, a row of tiles. If the line appears wavy, distorted, or has a gap or dark patch when viewed through one eye, that is worth a call to your GP or optician the same day. This is the Amsler grid principle used in optometry and it works just as well with a door frame as a printed grid. It is not a diagnostic tool, but it is a simple way to catch something that deserves attention before it becomes harder to treat.
Keeping brief notes (what you noticed, which eye, when, and whether it resolved) is also genuinely useful if you later need to describe the episode to a clinician. Our prescribers appreciate this kind of detail when patients raise concerns through our aftercare service. For a broader look at managing side effects through the early weeks, our guide to managing Wegovy side effects covers practical strategies alongside the clinical context.
If you are mid-treatment and something changes with your vision, the right first step is to pause and seek clinical input rather than adjusting your dose or stopping abruptly on your own. Contact your prescribing service (at nume, our aftercare team is available seven days a week) and speak to your GP or optician if the change is notable. Do not wait for your next scheduled review if the symptom is new, unexplained, or getting worse.
Stopping semaglutide abruptly is rarely necessary based on a vision change alone, but that is a clinical judgement made by your prescriber with the full picture, not a rule of thumb from a content page. The experience of people who have no notable side effects on Wegovy is common too, vision changes are not a certainty, and many people complete the full titration without noticing any eye-related symptoms.
If you are researching Wegovy before starting, you can learn more about what Wegovy is and how it works, or explore weight-loss treatment options more broadly. When you are ready to discuss your own health history with a prescriber, check your eligibility through a free consultation, vision history, including any current eye conditions, is part of the assessment.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.